

Index

a

accessory proteins 195
 – role 195
 acute myeloid leukemia 150
 adaptive immune system 29, 64
 adoptive T-cell therapy 10, 221
 adult cancer patients 115
 affinity immune receptors 209
 AFP peptide epitopes 24
 AFP-specific CTL 24
 agonistic antibodies 127
 allogeneic hematopoietic cell transplant 27
 allografted organs 237
 AMIDA technology 68, 71
 – advantages 71
 – disadvantages 71
 amino acid
 – composition 303
 – sequences 263, 303
 amniotic fluid 268
 amplified genes 52
 antibody dependent cellular cytotoxicity 197
 – activity 197
 anti apoptotic molecule 54
 antibody-antigen complexes 69
 antibody/interleukin 2 (IL-2) fusion proteins 209
 antibody/pseudomonas exotoxin fusion protein 192
 antibody therapies 24, 180, 195
 anticancer peptide vaccine 303
 antigen 3, 4, 5, 6, 7, 8
 – epithelial cells 205
 – repertoire 6, 8
 – specific vaccination 10
 – T cells 7, 9, 11, 24, 31
 – tumor 53
 antigen epitopes 4, 11

– generation 11
 antigen presenting cells (APC) 64
 antigen processing presentation machinery (APM) 67, 225
 antigenic determinants 67
 antigenic peptides 4
 antigenic protein 48, 57
 anti-idiotypic antibodies 143, 210
 antisense oligonucleotides 127
 anti-tumor immune response, *see* malignant cells
 antitumor immunity 210
 – immune responses 211, 222
 APM-related components 67
 apoptosis gene family 121
 – inhibitor 121
 arginine residues 263
 autoaggressive disorders 64
 autoimmune toxicity 7
 autologous tumor cells 9
 avian poxvirus vectors 211

b

B cell lymphoma 121
 β -microglobulin subunit 4
 bacterial artificial chromosome (BAC) 207
 bacterial expression system 55
 bacterial pathogens 204
 BCR/ABL protein 63, 119
 BCR/ABL-specific peptide vaccines 119
 bio conductor array 89
 bioinformatics systems 89
 bioinformatics tools 89
 biological contaminants 303
 biomarkers 63, 103
 BiTE antibodies 197
 breast cancer cells 181
 Burkitt's lymphoma cells 231, 232, 240

c

- calcium-independent homotypic cell
 - adhesion 180
- cancer-bearing host 80
- cancer-derived CSC 184
- cancer immunotherapies 219
- cancer-related autoantigens 146
- cancer-specific serum antibodies 64
- cancer stem cells (CSC) 184
- cancer testis antigens (CTA) 6, 26, 51, 121, 127, 143, 161, 162, 163, 164, 166, 167, 170, 172
 - based immunotherapy 148
 - based vaccination 148, 149
 - definitions 162
 - directed vaccines 151
 - expression 148, 161
 - GAGE 163
 - MAGE 163
 - positive lesions 148, 149
 - promoters 149
 - specific TCR repertoire 7
 - SSX 163
- cancer testis antigens families 124
 - BAGE 124
 - GAGE 124
 - MAGE 124
 - SAGE 124
 - XAGE 124
- cancer vaccines 23
 - development 23
- carbonic anhydrase expression 92
- carboxy-terminal 235
 - domain 265
- carcino embryonic antigen 26, 203
 - based immunotherapy 205
 - based vaccines 26
 - expression 203, 204
 - family 201, 204, 207
 - immune therapies 207
 - measurements 206
 - peptide 205
 - poxvirus vaccines 211
 - protein vaccines 207
 - serum levels 206
 - specific cytotoxic lymphocytes 210
 - targeted vaccination 204
 - transgenic mice 207, 209, 210
 - transgenic transplanted tumor models 210
 - vaccine-induced effector cells 212
- carcinogen-induced tumor cells 30
- carcinoma cells 65
- CCAAT enhancer binding protein 52
- CD4⁺ T cells 4
 - analysis 53
 - epitope 5
- CD8⁺ T cells 25
 - analysis 53
 - epitope 4
- cDNA amplification 83
- cDNA expression libraries 9, 48, 49, 66
- cDNA microarrays 82
 - analysis 82
 - data 88
 - utilization 82
- cell lung carcinomas 203
- cell lysates 23
- cell lysis buffer 83
- cell-pulsed dendritic cell vaccines 125
- cell signal transduction 181
- cell surface mucins 262
- cellular/humoral immune response 144, 171
- cellular immune responses 126, 209
- cellular proteins, *see* antigen
- cellular signaling components 235
- central nervous system 29
- cervical cancer 249
- chemo/antibody combination 187
- chemotherapy/cytokine therapy 304
- childhood malignancy 115
- chromatographic surface 105
- chromosomal translocation 63
- chronic myelogenous leukemia (CML) 63, 117
- circulating tumor cells (CTC) 184
- clonal theory 63
 - techniques 47
- co-stimulatory molecules 211
- colorectal cancer tissues 184
- complement-dependent cytotoxicity (CDC) 197, 183
 - activity 190
- Coomassie blue/silver nitrate 70
- coxsackie/adenovirus receptor 209
- colorectal cancer, 186, 192
 - bevacizumab 192
 - cetuximab 192
 - panitumumab 192
- CRC tumors 184
- cryptic promoters 6
- CTL-mediated lysis 120
- CTL precursor frequencies 309
- cysteine residues 265
- cytokine treatments 211
- cytoplasmic proteins 5
- cytotoxic T lymphocytes (CTL) 143
- cytotoxic T cells 47

d

DC-based vaccines 32
 DC growth factor 170
 delayed type hypersensitivity (DTH) 292
 dendritic cell 3, 9, 167
 dependent gene expression 68
 diagnostic imaging 125
 diagnostic markers 47
 disease-specific multimodal treatment protocols 115
 DNA-binding proteins 83, 233
 – RBP-J κ 233
 – utilization 83
 DNA cancer vaccines 287
 DNA-dependent RNA polymerase 85, 88
 DNA hypomethylating drug 144
 DNA methylation 144, 148, 152, 153, 162
 – analysis 147
 DNA methyltransferase enzymes 144
 DNA microarray gene expression data 89
 DNA plasmid vectors 223
 DNA sequencing 48
 DNA vaccines 287
 dose-dependent immunosuppressants 304
 double-stranded DNA viruses 249
 drug-induced demethylation 152

e

EFT, *see* Ewing family tumors
 EGF/PDGF-receptors 251
 EGFR, *see* epidermal growth factor receptor (EGFR)
 endocytosed exogenous antigens 5
 endoplasmic reticulum 5
 EpCAM 190, 194
 – antibody 193
 – epitope 189
 – expression 181, 186, 191, 196
 – immunotherapies 183, 192, 194, 196
 – positive tumor cells 188
 – promoter 193
 – protein 189, 194
 – protein complexes 195
 – specific antibodies 192
 – specific therapies 193, 197
 – staining 183
 epidermal growth factor receptor (EGFR) 30, 128, 220
 epigenetic drugs 149, 151
 epigenetic mechanisms, *see* DNA methylation
 epigenetic regulators 144
 epithelial cancer cells 147, 188, 253, 267
 epithelial cell surface 26

epithelial ovarian cancers 261
 epithelial tissues 193
 Epstein Barr Virus (EBV) 6, 231
 – associated tumors 122
 – infected cells 231, 237, 239
 – nuclear antigen 233
 – peptides 240
 – proteins 240
 – sero-negative recipients 239
 EBV-associated post-transplantation lymphoproliferative disease 122, 233
 ER-localized peptidases 11
 Ewing family tumors (EFT) 126
 – pathogenesis 126
 EWS gene 126
 exogenous proteins 5
 extracellular adhesive protein domain 205
 extracellular domain 202, 221
 ezrin/radixin/moesin (ERM) 267

f

Fc-binding motif 208
 fetal acetylcholine receptor (fAChR) 124
 fluorescence-activated cell sorting (FACS) 56
 fluorescence-labeled cDNA 88
 fluorogenic substrates 268
 Food and Drug Administration (FDA) 152, 221, 225, 284
 fusion genes 119
 fusion proteins 6, 146

g

GAGE families 121
 gametogenic cells 163
 gastrointestinal tract 192
 gene expression 81
 – data 89
 – mutations 6
 – ontology 89
 – quantification 81
 gene profiling arrays 80
 gene-specific hypomethylation 164
 genomic DNA 233, 263
 Glioblastoma multiforme 29
 glial fibrillary acidic protein (GFAP) 51
 glioma-associated antigens (GAAs) 30
 glioma cell lines 30
 good manufacturing practice (GMP) 287
 GPI-linked membrane proteins 262
 graft-versus-host disease (GVHD) 118
 graft-versus-leukemia (GVL) 27, 117
 growth factor receptors 124
 – EGF-R 124

- HER2 124
- GVAX vaccines 290
- gynecologic cancer intergroup (GCIG) 273

h

- HCC-associated antigens 68
- HDAC enzymes 145
- HDAC inhibitor 147
- head and neck squamous cell carcinomas (HNSCC) 106
- heat shock proteins 30, 31
- heavy chain alleles 4
- hemagglutinin protein chimera 208
- Hematopoietic malignancies* 27, 152
- hematopoietic stem cell transplantation (HSCT) 116, 118, 121
- heparin-binding growth factor 126
- hepatocellular carcinoma (HCC) 67, 163
 - autoantibodies 67
- HER receptors 220
- HER signal cascade 220
- HER2 kinase domain 224
- HER2-positive tumors 225
- heterodimerization signal transduction 225
- heterogeneous expression 148
- heterotypic interaction 205
- hierarchical clustering 89
- high-dose chemotherapy 126
- high affinity binders 9
- high throughput technology 92
- histone acetyltransferases (HAT) 145
- histone methyltransferase (HMT) 145
- Hodgkin lymphoma 240
- hormonal therapies 294
- hormone-resistant prostate cancer (HRPC) 292
- house keeping genes 80
- HSP-based vaccines 31
- human cancer immunome 54
- human chorionic gonadotropin (HCG) 103
- human epidermal growth factor receptor 179, 219
- human glioma antigens 29
- human immune effector cells 185
- human immunoglobulin repertoires 190
- human leukocyte antigen (HLA) 26, 150, 231
 - allele 29
 - antigens 118
 - class I antigen processing 25
 - class I-positive tumors 125
 - loading machinery 236
 - negative RMS cell lines 124
 - target cells 9
- human melanoma antigens 28–29
- human papilloma virus (HPV) 6, 249
 - antigens 254, 255
 - basal epithelial cells 249
 - encoded proteins 253
 - gene expression 251
 - induced cancer 249
 - infection 249, 250, 255, 256
 - malignancies 256
- human tumor antigen 5, 49, 54, 220
 - identification 49
- humoral/cellular immune response 26, 47, 64, 148
 - spontaneous 148
- hypopigmentary skin disorder 7

i

- immature dendritic cells 290
- immune cells 194, 195
- immune deviation 33
- immune effector cells 196
 - effector mechanisms 23
- immune electron microscopy 203
- immune inhibitory factors 10
 - IL-10 10
 - PGE-2 10
 - TGF- β 10
- immune-modulators 80
 - interleukin-2 80
- immune molecules 144
 - HLA antigens 144
- immune response 255, 284, 286, 287
- immune system 3, 23, 24, 55, 167, 204, 231, 238, 283
- immunohistochemistry 148, 161, 266
- immunopreventive vaccines 107
- immunoproteasome 4
- immunoreactive spots 67
- immunoreceptor-tyrosine-based-activation-motif (ITAM) 235
 - motifs 203
- immunosuppressive regulatory T cells 255, 256
- immunotherapeutic approaches 47, 143
- Incomplete Freund's Adjuvant (IFA) 29
- inflammatory cells 33
- innate/adaptive immune cells 3
- insulin-like growth factor (IGF) 127
- interferon stimulated genes (ISGs) 92
- intestinal intraepithelial lymphocytes 206
- intracellular signal cascade 146
- intraepithelial lesions 249
- intrasplinal tumors 115
- ionizing radiation 115

I

laser capture micro-dissection (LCM) 82
 lectin-like molecules 267
 leukemia cells 118
 leukocytes 69
 lineage-associated expression 51
 linear amplification 85
 LN-associated chemokines 32
 long control region (LCR) 250, 251
 low-risk tumors 127
 Ludwig Cancer Research Institutes 54
 lung carcinoma 68
 lymph nodes 3
 lymphoblastoid cell lines 235
 lymphoid system 253
 lysate-pulsed dendritic cells 127

m

macrophage migration inhibiting factor 91
 major histocompatibility complex (MHC) 3, 9, 27, 56, 57, 72, 211
 – antigen processing 67
 – class I molecules 3
 – class II molecules 4
 – ligands 9, 11, 212
 – multimer binding technology 211
 – peptides 4, 5
 male germline cells 26
 malignant bone tumor 125
 – identification 126
 – osteosarcoma 125
 malignant cells 10
 malignant tissues 146
 – CEBPg 146
 mammary epithelial cells 220
 MDA-specific T cells 7
 Meig's syndrome 270
 melanocytic lineage 28
 – antigen-processing machinery 28
 – gp100/pmel17 28
 – tyrosinase 28
 melanoma-associated antigens (MAA) 28
 – gene transcription 28
 – peptide epitopes 29
 melanoma antigen (MAGE) 161
 – antigens 7
 – expression 165
 – family 126
 – homology-domain 166
 – proteins 166
 melanoma cells 28, 150
 melanoma differentiation antigens 7, 79
 melanoma metastasis 8

melanoma mouse models 28
 metachronous hepatic metastases 183
 metastasizing cells 195
 metastatic disease 126, 169
 microarray-based technologies 79
 – introduction 79
 – technical aspects 80
 microbial ligands 202
 microbial receptors 202
 microdissected specimen 105
 – lysates 105
 microneedle-based injection systems 287
 microphthalmia transcription factor 91
 minimal residual disease (MRD) 116, 122
 – diagnosis 117
 – markers 119
 – PRAME 119
 – WT1 119
 missense mutations 25
 mitochondrial protein 52
 mitotic abnormalities 63
 model systems 225
 moloney murine leukemia virus 84
 monoclonal antibodies (mAb) 71, 128, 143, 180, 221
 – based therapies 179
 – Herceptin® (Trastuzumab) 71
 – technology 47, 65
 mouse fibroblasts 72
 mucin genes 147, 264
 – diagrammatic representation 264
 multiple benign diseases 270
 – gynecological 270
 – non-gynecological 270
 multiple sclerosis 64
 multiprotein complexes 145
 murine antibody 197
 murine dendritic cells 24
 murine immune system 191
 murine monoclonal antibody 267
 MYCN-derived peptides 123
 MYCN oncogene 122, 123
 myelodysplastic syndrome (MDS) 150
 myelogenous leukemia (AML) 117

n

N domain of murine 202
 N-glycosylation sites 264, 265
 N-linked glycan chains 264
 N-terminal domain 263
 N-terminal-extended precursors 5
 N-terminal tails 145
 natural killer (NK) cells 31, 64

- inhibitory receptor 205
- naturally-occurring autoantibodies (NAAs) 69, 70
- NB-associated antigens 122, 123
- identification 123
- Neisseria gonorrhoeae* 204
- Neisseria meningitides* 204
- neoplastic cells 143, 146
- phenotypic characterization 143
- neoplastic diseases 117
- neoplastic/malignant melanocytes 28
- neurological diseases 119
- neuron-specific enolase (NSE) 103
- nipple aspirate fluid (NAF) 106
- non-cancer-related autoantigens 52
- non-gynecological benign diseases 270
- non-Hodgkin lymphomas (NHL) 121
- non-lymphoid tissues 6
- non-myeloablative chemotherapy 11
- non-proliferating cells 256
- non-small cell lung (NSCLC) 220
- non-transformed autologous cells\leukocytes 69
- northern blot analysis 52
- nuclear signaling 181
- O**
- O-glycosylated residues 264
- O-linked glycoprotein 263
- oligo-based microarray systems 81
- oncofetal antigen 24
- oncogenic transformation 221
- P**
- p53 tumor suppressor gene 25, 65
- pancreatic ductal adenocarcinoma 165
- papillomavirus binding factor 126
- pattern recognition receptors 283
- PAX/FKHR fusion products 124
- PAX3/FKHR peptides 124
- PBMC donors 191
- pediatric cancer 116, 117
- pediatric malignancies 128
- pelvic inflammatory disease 270
- peptides 285
 - based vaccination 126, 293
 - binding motifs 4
 - epitopes 8, 255
 - fragments 57
 - ligands 4
 - MHC complexes 11
 - reactive T cells 9
 - specific immune responses 118
 - vaccination 285
- peripheral blood mononuclear cells (PBMC) 152, 190
- peripheral lymphoid organs 3
- peripheral tolerance 209
- personalized peptide vaccines (PPVs) 309
- plasma membrane-associated complex 72
- poly-adenosyl-ribosyl transferase 53
- polyepitope vaccines 170
- polymerase chain reaction (PCR) 82
 - amplification 86, 87
 - combination 87
 - cycles 87
 - limitations 86
- polymorphic epitopes 118
- polymorphic heavy chain 4
- polymorphonuclear leukocytes 33
- polyvalent vaccines 57
- positron emission tomography (PET) 208
- post-menopausal women 269, 270
- post-translational modifications 26, 48, 64, 67, 145
 - glycosylation 26, 48
 - identification 67
 - phosphorylation 26
- pregnancy-specific glycoprotein (PSG) 201
- pre-menopausal women 271
- pro-inflammatory mediators 254
 - interferons 254
- professional antigen presenting cells (pAPCs) 5
 - DCs 5
 - macrophages 5
- prognostic factor 191
- prognostic markers 125, 146
- programmed cell death 166
- proinflammatory cytokines 205
- proliferation signal 180
- prophylactic vaccines 23, 253
- prostate-specific antigen (PSA) 71, 103
- protein 9, 30
 - derived epitopes 236
 - endogenous 5
 - lysates 105
 - periplasmatic 48
- protein–protein interaction 204
- ProteinChip system 106
- ProteinChip technology 106
- PROTEOMEX 66
 - experiments 67
 - schematic view 66
 - technology 67
- proteomic analysis 275
- proteomics-based methods 64

- PROTEOMEX 64
- post-transplantation lymphoproliferative disease (PTLD) 237, 240
- specific tumor 238
- putative tyrosine phosphorylation site 265
- PVDF membranes 66

q

- quantitative real-time PCR 90

r

- radioisotope-conjugates 208
- radio-resistant tumors 295
 - melanoma 295
- RAS genes 25
 - mutations 25
- RAS oncogenes 25
- recombinant pox virus vectors 211
- recombinant proteins 48, 143, 286, 287
 - implementation 287
- renal cell cancers (RCC) 54, 66, 79
- reporter molecules 268
- respiratory papillomatosis 255
- reverse T Cell Immunology 53
- RNA amplification methods 82, 84
- RNA amplification technology 82, 85
 - modifications 82
 - optimizations 82
 - validations 82
- RNasin® Plus RNase inhibitor 83
- RNA degradation 82
- RNA polymerase 85
- RNA protection reagent 83
 - RNAlater™ 83
- reverse transcription polymerase chain reaction (RT-PCR) 180
- RMS-specific adoptive T-cell transfer 124

s

- SART3-positive tumors 126
- SART3-specific T cells 126
- screening technology 71
- screening tumor-derived cDNA expression libraries (SEREX) 64
- SEA domain sequences 264
- SELDI-MS technology 105
 - schematic representation 105
- SELDI-ProteinChip technology 106
- SEREX 146
 - approach 48, 117
 - database 54
 - method 119, 167
 - screening 128
 - technology 64, 166

- serologically-defined antigens 54
- sex hormone levels 106
- signaling pathway 181
- signaling proteins 8
 - phosphorylation 8
- significance analysis of microarrays (SAM) 89
- single-chain bispecific antibody 193
- small-cell lung cancers 208
- small interfering RNA 166
- solid organ transplantation 122
- squamous cell carcinoma express 180
- SSX antigen family 7, 51
- SSX gene 51, 148
- Streptococcus pyogenes* 283
- synthetic oligonucleotide probes 80
- synthetic peptides 167, 224
 - epitopes 10
- SYT gene 51

t

- T-cell antigens 8, 9, 11
 - epitopes 8
 - identification 8
- T cell-based therapy 10
- T-cell epitopes 4, 9, 223
 - generation 4–5
- T-cell receptor-mediated cytotoxicity 204
 - genes 203
- T-cell responses 193
- T-helper lymphocyte 48
- T cell-mediated immunotherapy 123
 - mechanisms 119
- target labeling 88
 - direct 88
 - indirect 88
- TAS-PCR primer 87
- T cell receptors 3
- tetramer-positive lymphocyte 292
- therapeutic agents 32
- therapeutic interventions 206
- therapeutic markers 72
- therapeutic vaccines 253
 - development 253
- therapeutic vaccination 31
- therapeutic vaccines target antigens 253
- time-of-flight mass spectrometry (MALDI-TOF) 104
- TMA staining 182
- TMA technology 182
- toll-like receptor agonists 92, 283
- transcription factor 250
- transcriptional profiling 90
 - limitations 90

- transgenic murine models 207
 - transitional cell carcinoma 107
 - translational repressor 53
 - transmembrane domain 265
 - transmembrane proteases 233
 - tumor-associated antigens (TAA) 5, 6, 10, 23, 25, 30, 31, 47, 48, 49, 53, 63, 64, 79, 91, 103, 116, 143, 146, 171, 172, 179, 206, 249, 251, 283, 303, 304
 - based active immunization 79
 - based immunotherapy 143
 - based vaccination 144
 - cancer-testis (CT) 26
 - classes 24
 - epitopes 8
 - human melanoma antigens 28
 - identification 10, 47
 - MAGE-1 49
 - minor histocompatibility antigens 27
 - molecular characterization 47, 79
 - oncofetal antigens 24
 - oncogenes 25
 - repertoire 10
 - specific vaccines 118
 - subclasses 5
 - targeted immunotherapies 211
 - tumor-bearing host 34, 47
 - tumor cells 6, 23, 167
 - cell lines 9
 - vaccines 289
 - tumor immunotherapy 116
 - tumor-derived antibodies 70, 107
 - libraries 47
 - purification 70
 - tumor-feeding vessels 82
 - tumor-host interactions 90
 - usefulness 90
 - tumor-infiltrating lymphocytes 33, 51, 256
 - characterization 256
 - tumor-localized antibody 208
 - tumor-reactive T cells 11
 - tumor-specific antigens 55, 283
 - tumor markers 206, 213
 - tumor necrosis factor 126
 - tumor suppressor gene 128
 - tumor therapies 207
 - tumor vaccine 119
 - tyrosine kinase 120
 - domain 223
 - inhibitors 120, 221, 222
 - peptides 286
 - receptor 30
 - residues 235
- u**
- ubiquitin carboxyl terminal hydrolase (UCHL) 67
- v**
- vaccine development 56
 - perspectives 56
 - vaccine-induced immunity 33
 - viral genes 233
 - epitopes 233
 - viral oncoproteins 6
 - E6 6
 - E7 6
 - viral vectors 172
 - pox viruses 172
 - virus-derived antigenic epitopes 238
 - virus-encoded antigen 52
 - virus-induced cancer 311
- w**
- Wilms' tumor protein 1 (WT1) 118
 - wnt pathway 181, 185
 - women menstrual cycle 270
 - World Health Organization 231
 - WT xenografts 128
- x**
- X-ray crystallography 202